Retina/Vitreous

Top Story

BLOG: Why are you taking that?

June 24, 2016

A long-time patient presented for an exam the other day. This is a patient that I look forward to seeing, as we have some common interests that we chat about during his exam.

He remarked that he really enjoyed coming for his exam, because he felt secure in the advice I give him. However, he also stated he has recently experienced an unsettled feeling in having to find a new primary care provider due to insurance changes.

In the Journals

AAO revises screening guidelines for chloroquine, hydroxychloroquine retinopathy

June 23, 2016
The American Academy of Ophthalmology revised its recommendations on screening for chloroquine and hydroxychloroquine retinopathy based on new information about the…

Ophthotech completes patient recruitment for third phase 3 trial of Fovista

June 23, 2016
Ophthotech has completed patient recruitment for a phase 3 clinical trial of Fovista in combination with anti-VEGF agents for the treatment of wet age-related macular…

Smartphone technology facilitates retinal exam in primary care

June 21, 2016
The use of smartphones as ophthalmoscopes with the D-Eye retinal adapter and app is user friendly and “may help revive retinal examination in primary care,”…

AOA warns consumers, alerts FDA of online vision tests

June 22, 2016
The American Optometric Association is educating consumers on the risks and limitations of online vision tests that…
More »

Smartphone technology facilitates retinal exam in primary care

June 21, 2016
The use of smartphones as ophthalmoscopes with the D-Eye retinal adapter and app is user friendly and “may help…
More »
Featured
ARVO

ARVO

Perspectives on Glaucoma

Glaucoma exams, treatment at community-based sites improve access to care

June 17, 2016
Researchers targeted individuals at risk for glaucoma in underserved Philadelphia communities, resulting in a detection…
More »

BLOG: Why are you taking that?

June 24, 2016
A long-time patient presented for an exam the other day. This is a patient that I look forward to seeing, as we have some common interests that we…

In the Journals

AAO revises screening guidelines for chloroquine, hydroxychloroquine retinopathy

June 23, 2016
The American Academy of Ophthalmology revised its recommendations on screening for chloroquine and hydroxychloroquine retinopathy based on new…

Ophthotech completes patient recruitment for third phase 3 trial of Fovista

June 23, 2016
Ophthotech has completed patient recruitment for a phase 3 clinical trial of Fovista in combination with anti-VEGF agents for the treatment of wet…

Smartphone technology facilitates retinal exam in primary care

June 21, 2016
The use of smartphones as ophthalmoscopes with the D-Eye retinal adapter and app is user friendly and “may help revive retinal examination in…

Meeting News CoverageVideo

VIDEO: OCT-guided AMD management

June 20, 2016
KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting, David M. Brown, MD, FACS, discusses the use of OCT to manage patients with age-related macular…

Meeting News CoverageVideo

VIDEO: Treatment with aflibercept for recalcitrant DME

June 19, 2016
KIAWAH ISLAND, S.C. — At the Kiawah Eye meeting, Scott Gardner, MD, discusses his experience with the use of Regeneron's Eylea (aflibercept) for…

In the Journals

Higher BMI, geographic atrophy may suggest poor response to aflibercept

June 16, 2016
Elevated body mass index and presence of geographic atrophy may be associated with a poor response to aflibercept in patients with age-related…

Bausch + Lomb launches AREDS 2, multivitamin combination

June 16, 2016
Bausch + Lomb introduced PreserVision AREDS 2 Formula + Multivitamin, which contains the Age-Related Eye Disease Study 2 formula with other vitamins…

In the JournalsFrom OSN APAO

Polypoidal choroidal vasculopathy with multiple polyps has poorer response to ranibizumab

June 15, 2016
Polypoidal choroidal vasculopathy with multiple polyps did not respond as well to intravitreal ranibizumab as polypoidal choroidal vasculopathy with…

Eleven Biotherapeutics, Roche enter exclusive license agreement for IL-6 antagonist antibody technology

June 14, 2016
Eleven Biotherapeutics has entered into an exclusive license agreement with Roche to develop and commercialize EBI-031 and other IL-6 antagonist…

More Headlines »
morganatic-roan morganatic-roan